Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05884333 · ClinicalTrials.gov registry record · Phase 2

Cord Blood Transplant in Adults With Blood Cancers

A Phase 2 study of Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia (ALL), sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
54
Enrollment target
1
Study location

NCT05884333 is a Phase 2 study of Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia (ALL) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 54 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05884333, a Phase 2 study of Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia (ALL), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.

Conditions Studied

Non-Hodgkin's Lymphoma Acute Lymphoblastic Leukemia (ALL) Myelodysplastic Syndromes (MDS) Acute Myelogenous Leukemia (AML) Chronic Myelogenous Leukemia (CML) Myeloproliferative Disorder

Interventions

  • DRUG Conditioning Chemotherapy
  • BIOLOGICAL Cord blood graft

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2023-05-22
Est. Completion 2028-05-22
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05884333

The ClinicalTrials.gov registry entry for NCT05884333 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (76% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Conditioning Chemotherapy is the first listed.

NCT05884333 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05884333 about?

NCT05884333 is a clinical study titled "Cord Blood Transplant in Adults With Blood Cancers". Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and ...

What is the current status of trial NCT05884333?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2023-05-22. Estimated completion is 2028-05-22.

What conditions does trial NCT05884333 study?

This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML).

What interventions are being tested in trial NCT05884333?

The interventions under investigation include: Conditioning Chemotherapy (DRUG), Cord blood graft (BIOLOGICAL).

Who is sponsoring clinical trial NCT05884333?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05884333 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin's Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin's Lymphoma

All registered trials for this condition

Acute Lymphoblastic Leukemia (ALL)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.